Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. (Q40476622)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

0 references

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anna Szmigielska-Kaplon

2

object named as

Anna Szmigielska-Kaplon

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

7

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Krzysztof Jamroziak

4

object named as

Krzysztof Jamroziak

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Piotr Smolewski

1

object named as

Piotr Smolewski

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Barbara Cebula

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Małgorzata Rogalinska

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Zofia Kilianska

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

87-100

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Alemtuzumab in T-cell malignancies

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Induction of apoptosis by cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Dissecting the pathways to death

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Perforin-dependent nuclear targeting of granzymes: A central role in the nuclear events of granule-exocytosis-mediated apoptosis?

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Detection of caspases activation by fluorochrome-labeled inhibitors: Multiparameter analysis by laser scanning cytometry

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: Bio-blots

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1080%2F13693780400007151

21 January 2018

Identifiers

10.1080/13693780400007151

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40476622&oldid=1561112333"